Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Description:
Faculty: Joyce F. Liu, MD, MPH
Faculty: Kathleen Moore, MD, MS
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the...